Rohto Pharmaceutical Co (Rohto Pharmaceutical Co) Total Current Assets : $1,487.66 Mil (As of Dec. 2023)

View and export this data going back to 2010. Start your Free Trial

What is Rohto Pharmaceutical Co Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Rohto Pharmaceutical Co's total current assets for the quarter that ended in Dec. 2023 was $1,487.66 Mil.

Rohto Pharmaceutical Co Total Current Assets Historical Data

The historical data trend for Rohto Pharmaceutical Co's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rohto Pharmaceutical Co Total Current Assets Chart

Rohto Pharmaceutical Co Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Total Current Assets

Get a 7-Day Free Trial

1,213.98

1,224.21

1,385.64

1,423.31

1,433.46

Rohto Pharmaceutical Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Current Assets	Get a 7-Day Free Trial															1,423.31	1,387.51	1,405.15	1,487.66	1,433.46

Rohto Pharmaceutical Co Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Rohto Pharmaceutical Co's Total Current Assets for the fiscal year that ended in Mar. 2024 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	595.453	+	298.655	+	311.423	+	227.929
	=	1,433.46

Rohto Pharmaceutical Co's Total Current Assets for the quarter that ended in Dec. 2023 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	568.663	+	344.641	+	336.821	+	237.538
	=	1,487.66

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Rohto Pharmaceutical Co (OTCPK:RPHCF) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Rohto Pharmaceutical Co's Liquidation Value for the quarter that ended in Dec. 2023 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	568.663	-	667.794	+	0.75 * 344.641	+	0.5 * 336.821
=	327.76

Rohto Pharmaceutical Co Total Current Assets Related Terms

Thank you for viewing the detailed overview of Rohto Pharmaceutical Co's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Rohto Pharmaceutical Co (Rohto Pharmaceutical Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Rohto Pharmaceutical Co Ltd (OTCPK:RPHCF) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

4527:Mexico 4527:Japan

Address

1-8-1, Tatsumi-nishi, Ikuno-ku, Osaka, JPN, 544-8666

Website

https://www.rohto.co.jp

Rohto Pharmaceutical Co Ltd is a Japan-based manufacturer and marketer of pharmaceutical products, cosmetics, and functional foods. It undertakes manufacture and sales activities mainly in the health and beauty care categories. The company comprises the four geographical reportable segments of Japan, America, Europe, and Asia. In each segment, it manufactures and sales eye care products including eye drops and eyewash preparations, skincare products including dermal medicines, lip balm, sunscreens, and functional cosmetics, among others, internal medicines and food products including gastrointestinal medicines, traditional Chinese herbal medicines and supplements, and other products and services, such as in-vitro test kits.

Rohto Pharmaceutical Co (Rohto Pharmaceutical Co) Headlines

From GuruFocus

Hennessy Japan Fund Semi-Annual Report April 30, 2014

By Vera Yuan Vera Yuan • 06-26-2014

Hennessy Japan Fund Comments on Rohto Pharmaceutical Co., Ltd.

By Vera Yuan Vera Yuan • 06-26-2014